News

RIVANNA announces award from U.S. government to develop Accuro Platform for rapid triage of blast-related injuries

RIVANNA®, developers of imaging-based medical solutions, announced that they have received a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the design and development of a computer-aided 3D fracture detection and diagnosis product, called Accuro® XV. Under the contract 75A50121C00035, HHS/ASPR/BARDA will provide $11.6 million over 24 months with options for additional funding for supporting further development up to $65 million.

The project’s overarching objective is to achieve a market-ready, clinically proven and FDA-cleared Accuro XV product for rapid, radiation-free fracture detection and aid triage in emergency medicine; a critical medical countermeasure to ensure timely triage for reduction of morbidity and mortality in mass-casualty blast trauma incidents, for which, no field-deployable equipment for extremity fractures currently exists.

The Accuro XV is a portable medical system building on novel technologies that underpin RIVANNA’s extensive patent portfolio, including BoneEnhance® Multi-Frequency Image Reconstruction, which optimizes ultrasound for the visualization of bony versus soft-tissue anatomy. Supporting this image reconstruction technology is Multi-Probe Multi-Angle BoneVision™, an automated image-acquisition technique based on a series of novel three-dimensional ultrasound-based bone-imaging technologies that increases angular image sensitivity to bone surfaces. BoneVision provides precisely captured bony anatomical structures within a large field of view and demonstrated performance detecting small fractures with high sensitivity and specificity.

By automating both the image acquisition and image interpretation, Accuro XV will also support just-in-time training, ideal for mass-casualty incidents; the ease of use afforded by the automation will reduce user dependence and optimize the success of clinical evaluations for adoption in hospital and emergency room (ER) settings.

Will Mauldin, PhD, co-founder, and CEO of RIVANNA, commented, “We are pleased to receive this award from BARDA. With attainment of targeted product performance specifications, the clinical and economic value of Accuro XV is expected to result in an inevitable shift away from the current state of X-ray overutilization towards a radiation-free, bedside triage standard of care.”

 

To learn more please visit RIVANNA

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns